1-benzyl-4-(3-fluorophenylamino)piperidine-4-carbonitrile | 885115-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-(3-fluorophenylamino)piperidine-4-carbonitrile
• 英文别名: 1-Benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carbonitrile；1-benzyl-4-(3-fluoroanilino)piperidine-4-carbonitrile
• CAS: 885115-40-2
• 化学式: C₁₉H₂₀FN₃
• 分子量: 309.386
• InChiKey: ZYEZCOWVFGHFHO-UHFFFAOYSA-N

物化性质

• 沸点：
  473.6±45.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  39.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-(3-fluorophenylamino)piperidine-4-carbonitrile 在 硫酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 18.0h， 生成 1-benzyl-4-((3-fluorophenyl)amino)piperidine-4-carboxamide
  参考文献：
  名称：

  WO2006/44497

  摘要：

  公开号：
• 作为产物：
  描述：

  N-苄基哌啶酮 、 3-氟苯胺 、 三甲基氰硅烷 在 溶剂黄146 、 氨 作用下， 以 水 为溶剂， 反应 1.0h， 生成 1-benzyl-4-(3-fluorophenylamino)piperidine-4-carbonitrile
  参考文献：
  名称：

  WO2006/44497

  摘要：

  公开号：

文献信息

• Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease
  申请人：Barrow C. James

  公开号：US20070197571A1

  公开（公告）日：2007-08-23

  The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式（I）的螺环哌啶化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在治疗β-分泌酶酶参与的疾病中的使用。
• BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Stauffer Shaun R.

  公开号：US20100076004A1

  公开（公告）日：2010-03-25

  The present invention is directed to bicyclic spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式（I）的双环螺环吡啶化合物，其为β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Merck, Sharp & Dohme Corp.

  公开号：US08114887B2

  公开（公告）日：2012-02-14

  The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的螺环吡啶化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶涉及的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在治疗β-分泌酶酶涉及的疾病中的应用。
• Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
  申请人：Stauffer Shaun R.

  公开号：US08377954B2

  公开（公告）日：2013-02-19

  The present invention is directed to bicyclic spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式（I）的双环螺内酯哌啶类化合物，它们是β-分泌酶酶的抑制剂，可用于治疗β-分泌酶酶参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在治疗β-分泌酶酶参与的疾病方面的用途。
• Triaza-spirodecanones as DDR1 inhibitors
  申请人：Hoffmann La-Roche Inc.

  公开号：US10239876B2

  公开（公告）日：2019-03-26

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

  本发明涉及式（I）化合物： 或其药学上可接受的盐，其中 L 和 R1 至 R5 如本文所述，以及它们的制造工艺、包含它们的药物组合物和它们作为药物的用途。